



(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 39/00 (2006.01)
A61P 37/06 (2006.01) A61M 5/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2022/060669

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/178,750 23 April 2021 (23.04.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **STREICHER, Katie**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **LINDHOLM, Catharina**; AstraZeneca AB, SE-151 85 Södertälje (SE). **CHIA, Yen Lin**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **TUMMALA, Rajen-**

dra; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **ROSKOS, Lorin**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ALMQUIST, Joachim**; AstraZeneca AB, SE-151 85 Södertälje (SE). **ROUSE, Tomas**; AstraZeneca AB, SE-151 85 Södertälje (SE). **MERRILL, Joan**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WERTH, Victoria**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

(54) Title: TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS

FIG 1

Distribution of IFN transcript scores



(57) Abstract: The disclosure relates to methods and compositions for the treatment of Cutaneous Lupus Erythematosus (CLE). Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.

[Continued on next page]

RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*